Alimera Sciences And pSivida Corp. Skyrocket On ILUVIEN (NASDAQ:ALIM), (NASDAQ:PSDV)

Alimera Sciences, Inc. (NASDAQ:ALIM)

As Wall STreets skeptical traders start to realize that the Federal Reserve Chairman Ben Bernanke has always had their back, we would advise you to check out Alimera Sciences, Inc. ticker symbol ALIM. This Company’s (www.alimerasciences.com) stock has skyrocketed +69.80% Up 1.78 generating over two point eight million shares in the financial markets at $4.33 per share Thursday December 19, 2013 Real-time: 11:39AM EST. Alimera Sciences, Inc. is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, headquartered in Alpharetta, Georgia. The HOT topic amongst investors surrounding Alimera Sciences, Inc. is ILUVIEN®.

Alimera Sciences, Inc. reached an agreement with the Food and Drug Administration that Alimera Sciences participation in the January 2014 Dermatologic and Ophthalmic Advisory Committee meeting was no longer necessary. Alimera will focus instead on drafting its response to the Complete Response Letter (CRL) received from the Food and Drug Administration in October 2013 with a goal of submitting the response this coming Q114. Stock market investors are thrilled, reason being that this allows Alimera Sciences to cut through the red tape and procceed with other previous matters put on hold concerning ILUVIEN®. This places ILUVIEN® one step closer towards reaching Food and Drug Administration approval. The Dynamics of this product is quite intriguing since receiving marketing authorization approval in Austria, France, Germany, Portugal, Spain and the United Kingdom.

****

pSivida Corp. (NASDAQ:PSDV)

With investor mOmentum building around concerns of ILUVIEN®, we would advise you to check out pSivida Corp. ticker symbol PSDV. This Company’s (www.psivida.com) stock has surged +42.11% Up 1.25 generating over two point five million shares in the financial markets at $4.22 per share Thursday December 19, 2013 Real-time: 12:11PM EST. pSivida Corp. develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. The HOT topic amongst investors surrounding pSivida Corp. is ILUVIEN®.

If ILUVIEN® becomes approved by the Food and Drug Administration, pSivida Corp. will be entitled to a $25 million milestone payment from Alimera Sciences, Inc. and 20% net profit sales of ILUVIEN for Diabetic Macular Edema by Alimera Sciences in the United States. Stock market analyst are speculating the impact ILUVIEN potentially could bring after receiving a +323% increase in income on Alimera Sciences Q313 financials, when compared to its prior Q213 from Germany and the United Kingdom sales. Which brings us to the duck test. If it looks like a duck, swims like a duck, and quacks like a duck, then its probably is a duck.

****

Other stock’s that need not to be over looked in the Wall Street Financial District:

Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) $5.70 (+33.69%) Up 1.44 Thursday December 19, 2013 Real-time: 12:28PM EST

Astrotech Corp. (NASDAQ:ASTC) $3.03 (+17.90%) Up 0.46 Thursday December 19, 2013 Real-time: 12:29PM EST

Remember: Always do your homework and consult your own financial professional.

Read Full Disclaimer at http://crweselect.com/disclaimer/